New Phase II Trial Combines Radiotherapy and Immunotherapy for Sarcoma

Soft Tissue Sarcoma (STS) represents a diverse group of rare and aggressive cancers originating in connective tissues, often posing significant challenges for effective treatment due to their heterogeneity and propensity for recurrence and metastasis. Current standard therapies, including surgery, chemotherapy, and conventional radiation, frequently lead to suboptimal outcomes for many patients, highlighting an urgent need for innovative therapeutic strategies. This study aims to evaluate the efficacy and safety of a novel combination of spatially fractionated radiotherapy with the PraG strategy to improve outcomes for STS patients.

As this study is "NOT_YET_RECRUITING" and is scheduled to commence in February 2026, there are no actual findings or results to report at this time. However, the primary objective is to rigorously evaluate the efficacy and safety of the combined spatially fractionated radiotherapy and PraG strategy in treating Soft Tissue Sarcoma (STS). The trial will specifically measure key efficacy endpoints, including the Objective Response Rate (ORR), which quantifies tumor shrinkage, as well as Progression-Free Survival (PFS), indicating how long patients live without their disease worsening, and Overall Survival (OS). The study's main goal is to determine if this innovative combination therapy can achieve a clinically meaningful Objective Response Rate (ORR) and improve survival outcomes for STS patients, compared to historical data for standard treatments. Safety will be comprehensively assessed by monitoring the incidence and severity of Adverse Events (AEs), ensuring the treatment is tolerable. The study aims to provide crucial data on the clinical benefit and safety profile of this novel approach, which could represent a significant advancement if successful.